News

/News/

The Bioscience Sector in Atlantic Canada

By | August 14th, 2017|Blog, Health Innovation Nation|

The Bioscience Sector in Atlantic Canada By Matthew Johnson   As Canada’s leading healthcare-focused investment firm, Bloom Burton & Co. seeks to develop strong connections to health and bioscience innovation clusters across the country. In this new blog series, Matthew Johnson, VP Business Development, will recount experiences traveling across this “Health Innovation Nation”. There’s no [...]

Are Canadian Universities Excelling at Teaching?

By | August 10th, 2017|Beyond the Bench, Blog|

Are Canadian Universities Excelling at Teaching? By Wayne Schnarr In his previous post, Wayne tackled the question of whether universities were doing enough to balance their teaching priorities with their research commitments. In this post he talks about excellence in teaching, and proposes a new teaching model that ensures university students are taught not only [...]

Canada in Science – August 4, 2017

By | August 4th, 2017|Blog, Canada in Science|

Welcome to your Canada in Science Review for August 4th, 2017!   Immunity. 2017 Jul 18;47(1):93-106.e7. Peroxisome-Mediated Metabolism Is Required for Immune Response to Microbial Infection. Stem Cells. 2017 Jul 31. doi: 10.1002/stem.2655. Brief Report: Human Acute Myeloid Leukemia Reprograming to Pluripotency Is a Rare Event and Selects for Patient Hematopoietic Cells Devoid of Leukemic Mutations. J Allergy [...]

Canada in Science – July 21, 2017

By | July 21st, 2017|Blog, Canada in Science|

Welcome to your Canada in Science Review for July 21st, 2017!   Nat Med. 2017 Jul 17. doi: 10.1038/nm.4367. Correction of a splicing defect in a mouse model of congenital musculardystrophy type1A using a homology-directed-repair independent mechanism. Cell. 2017 Jul 13;170(2):324-339.e23. Regulatory Expansion in Mammals of Multivalent hnRNP Assemblies that Globally Control Alternative Splicing. Cell Stem Cell. 2017 Jul 11. [...]

Q2 Share Price Performance in 2017 – Part 3

By | July 19th, 2017|Analysis, Blog, Capital Markets|

In the final instalment of this analysis, I will comment on the Q2 and H1 2017 share price performance of the group of 65 companies with share prices of between $0.10 and $0.99 to start 2017 (excludes Immunotec which was taken private in Q2). Overall, Tier 2 Canadian healthcare companies had a moderately negative performance [...]

Are Canadian Universities Balancing and Excelling at Teaching and Research?

By | July 13th, 2017|Beyond the Bench, Blog|

Are Canadian Universities Balancing and Excelling at Teaching and Research? By Wayne Schnarr In this article, Wayne looks at how universities have changed through the years, from when he first graduated in 1967, to today. He ponders over the always relevant but sometimes controversial question of whether universities are doing enough to balance their dual [...]

Q2 Share Price Performance in 2017 – Part 2

By | July 12th, 2017|Analysis, Blog, Capital Markets|

          Overall, Tier 1 Canadian Healthcare Companies had a negative performance driven by one group of companies. In this article, I am going to comment on the Q2 and H1 performance of the group of 53 companies with share prices of $1.00 or more to start 2017. Q2 2017 Summary Decliners almost [...]

Canada in Science – July 11, 2017

By | July 11th, 2017|Blog, Canada in Science, Commentary|

Welcome to your Canada in Science Review for July 11th, 2017!   Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):7124-7129. Microbial glycoside hydrolases as antibiofilm agents with cross-kingdom activity. Curr Biol. 2017 Jun 20. pii: S0960-9822(17)30650-4. Differential Control of Dopaminergic Excitability and Locomotion by Cholinergic Inputs in Mouse Substantia Nigra. PLoS Biol. 2017 Jun 20;15(6):e2001930. MAIT cells launch [...]

Q2 Share Price Performance in 2017 – Part 1

By | July 6th, 2017|Blog, Capital Markets|

  Overall, Q2 2017 share price performance in the sector was mixed with high volatility. A top-line look at the combined Tier 1 and 2 share price changes shows that despite a poor Q2 (-4.9%), the first half was still positive (+4.9%). However, a topline look always needs to be followed by a detailed analysis. The [...]

Titan Medical Inc. Announces Closing of Public Offering

By | June 30th, 2017|Bloom Burton, Financing, News|

Click image to read the full news release.